Literature DB >> 11741832

TSC2 missense mutations inhibit tuberin phosphorylation and prevent formation of the tuberin-hamartin complex.

M Nellist1, B Verhaaf, M A Goedbloed, A J Reuser, A M van den Ouweland, D J Halley.   

Abstract

Tuberous sclerosis (TSC) is an autosomal dominant disorder characterized by a broad phenotypic spectrum that includes seizures, mental retardation, renal dysfunction and dermatological abnormalities. Inactivating mutations to either of the TSC1 and TSC2 tumour suppressor genes are responsible for the disease. TSC1 and TSC2 encode two large novel proteins called hamartin and tuberin, respectively. Hamartin and tuberin interact directly with each other and it has been reported that tuberin may act as a chaperone, preventing hamartin self-aggregation and maintaining the tuberin-hamartin complex in a soluble form. In this study, the ability of tuberin to act as a chaperone for hamartin was used to investigate the tuberin-hamartin interaction in more detail. A domain within tuberin necessary for the chaperone function was identified, and the effects of TSC2 missense mutations on the tuberin-hamartin interaction were investigated to allow specific residues within the central domain of tuberin that are important for the interaction with hamartin to be pin-pointed. In addition, the results confirm that phosphorylation may play an important role in the formation of the tuberin-hamartin complex. Although mutations that prevent tuberin tyrosine phosphorylation also inhibit tuberin-hamartin binding and the chaperone function, our results indicate that only hamartin is phosphorylated in the tuberin-hamartin complex.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11741832     DOI: 10.1093/hmg/10.25.2889

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  28 in total

Review 1.  Positive and negative regulation of TSC2 activity and its effects on downstream effectors of the mTOR pathway.

Authors:  Jaroslaw Jozwiak; Sergiusz Jozwiak; Tomasz Grzela; Maciej Lazarczyk
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

Review 2.  Signaling by target of rapamycin proteins in cell growth control.

Authors:  Ken Inoki; Hongjiao Ouyang; Yong Li; Kun-Liang Guan
Journal:  Microbiol Mol Biol Rev       Date:  2005-03       Impact factor: 11.056

3.  Analysis of TSC1 mutation spectrum in mucosal melanoma.

Authors:  Meng Ma; Jie Dai; Tianxiao Xu; Sifan Yu; Huan Yu; Huan Tang; Junya Yan; Xiaowen Wu; Jiayi Yu; Zhihong Chi; Lu Si; Chuanliang Cui; Xinan Sheng; Yan Kong; Jun Guo
Journal:  J Cancer Res Clin Oncol       Date:  2017-11-28       Impact factor: 4.553

4.  Successful treatment of a TSC2-mutant glioblastoma with everolimus.

Authors:  Andrew H Zureick; Kathryn A McFadden; Rajen Mody; Carl Koschmann
Journal:  BMJ Case Rep       Date:  2019-05-31

5.  Genotype and cognitive phenotype of patients with tuberous sclerosis complex.

Authors:  Agnies M van Eeghen; Margaux E Black; Margaret B Pulsifer; David J Kwiatkowski; Elizabeth A Thiele
Journal:  Eur J Hum Genet       Date:  2011-12-21       Impact factor: 4.246

Review 6.  The tuberous sclerosis complex.

Authors:  Ksenia A Orlova; Peter B Crino
Journal:  Ann N Y Acad Sci       Date:  2010-01       Impact factor: 5.691

7.  A reliable cell-based assay for testing unclassified TSC2 gene variants.

Authors:  Ricardo Coevoets; Sermin Arican; Marianne Hoogeveen-Westerveld; Erik Simons; Ans van den Ouweland; Dicky Halley; Mark Nellist
Journal:  Eur J Hum Genet       Date:  2008-10-15       Impact factor: 4.246

8.  Update on the cytogenetics and molecular genetics of chordoma.

Authors:  Lidia Larizza; Pietro Mortini; Paola Riva
Journal:  Hered Cancer Clin Pract       Date:  2005-02-15       Impact factor: 2.857

9.  Tsc2 is not a critical target of Akt during normal Drosophila development.

Authors:  Jixin Dong; Duojia Pan
Journal:  Genes Dev       Date:  2004-10-01       Impact factor: 11.361

10.  Genetics and molecular biology of tuberous sclerosis complex.

Authors:  Valerio Napolioni; Paolo Curatolo
Journal:  Curr Genomics       Date:  2008-11       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.